ArticleCureus2026
The MRI Spectrum of Gynecological Pelvic Masses.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGynecological pelvic masses comprise a wide spectrum of benign and malignant conditions. Accurate preoperative characterization is crucial for optimal management. Although ultrasonography is the initial imaging modality, magnetic resonance imaging (MRI) provides superior soft-tissue characterization and multiplanar assessment.
objectiveTo evaluate the role of MRI in the characterization and differentiation of gynecological pelvic masses, using histopathology as the gold standard wherever available. MATERIALS AND
methodsThis observational study included 60 patients with gynecological pelvic masses detected clinically or on ultrasonography who subsequently underwent MRI pelvis. MRI sequences included T1-weighted, T2-weighted, diffusion-weighted, and contrast-enhanced imaging. Lesions were assessed for site of origin, morphology, internal characteristics, and extent, and MRI findings were correlated with histopathological diagnoses.
resultsBenign lesions constituted the majority of cases. Leiomyoma was the most common pathology, observed in 22 patients (36.7%), followed by adenomyosis in 12 patients (20.0%) and ovarian cysts (simple or hemorrhagic) in 11 patients (18.3%). Other benign lesions included dermoid cysts and tubal pathologies such as hydrosalpinx. Malignant lesions were identified in a smaller proportion of patients, with ovarian carcinoma being the most frequent malignancy (four cases, 6.7%), followed by endometrial carcinoma (three cases, 5.0%) and cervical carcinoma (one case, 1.7%). MRI correctly identified all ovarian lesions, including ovarian carcinomas, cysts, and dermoid cysts, as well as all cases of endometrial and cervical carcinoma. Overall, MRI demonstrated a sensitivity of 100%, specificity of 96.2%, and diagnostic accuracy of 96.7% in differentiating benign from malignant lesions.
conclusionMRI is a highly accurate and reliable imaging modality for the evaluation of gynecological pelvic masses, offering excellent lesion characterization and differentiation, thereby significantly aiding clinical decision-making and preoperative planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.